Toth Financial Advisory Corp Boosts Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Toth Financial Advisory Corp increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 34.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,500 shares of the company’s stock after buying an additional 1,413 shares during the period. Toth Financial Advisory Corp’s holdings in Neurocrine Biosciences were worth $759,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Neurocrine Biosciences in the third quarter worth about $276,000. FMR LLC increased its stake in shares of Neurocrine Biosciences by 129.6% in the third quarter. FMR LLC now owns 22,005 shares of the company’s stock worth $2,476,000 after purchasing an additional 12,420 shares in the last quarter. Mariner LLC increased its stake in shares of Neurocrine Biosciences by 6.5% in the third quarter. Mariner LLC now owns 10,978 shares of the company’s stock worth $1,235,000 after purchasing an additional 670 shares in the last quarter. Stifel Financial Corp increased its stake in shares of Neurocrine Biosciences by 25.4% in the third quarter. Stifel Financial Corp now owns 18,794 shares of the company’s stock worth $2,114,000 after purchasing an additional 3,802 shares in the last quarter. Finally, Natixis Advisors L.P. increased its stake in shares of Neurocrine Biosciences by 22.5% in the third quarter. Natixis Advisors L.P. now owns 30,343 shares of the company’s stock worth $3,414,000 after purchasing an additional 5,573 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the transaction, the insider now owns 40,778 shares in the company, valued at $5,438,154.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the sale, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gary A. Lyons sold 12,500 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total value of $1,695,375.00. Following the completion of the sale, the director now directly owns 116,947 shares of the company’s stock, valued at approximately $15,861,521.61. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 88,697 shares of company stock worth $11,975,615. Insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NBIX. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Wednesday, May 1st. JPMorgan Chase & Co. raised their price objective on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Canaccord Genuity Group raised their price objective on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Guggenheim raised their price objective on shares of Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Finally, Evercore ISI assumed coverage on shares of Neurocrine Biosciences in a research report on Tuesday, May 14th. They set an “outperform” rating and a $175.00 target price for the company. Six research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $152.00.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $137.67 on Friday. Neurocrine Biosciences, Inc. has a 52-week low of $93.02 and a 52-week high of $148.37. The stock has a market capitalization of $13.86 billion, a price-to-earnings ratio of 37.93 and a beta of 0.36. The company’s 50 day moving average price is $137.34 and its 200-day moving average price is $135.72.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The firm had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. As a group, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.